

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Multiple Technology Appraisal

**Everolimus, lanreotide, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression [ID838]**

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Imaging Equipment (lutetium - 177)</li> <li>• Ipsen (lanreotide)</li> <li>• Novartis (everolimus)</li> <li>• Pfizer (sunitinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Radiotherapy</li> <li>• Beating Bowel Cancer</li> <li>• Black Health Agency</li> <li>• Bowel Cancer Information</li> <li>• Bowel Cancer UK</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Pancreatic Cancer Action</li> <li>• Pancreatic Cancer UK</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• The NET Patient Foundation</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Coloproctology of Great Britain</li> <li>• Bladder and Bowel Foundation</li> <li>• British Geriatrics Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (5-fluorouracil, doxorubicin)</li> <li>• Allergan UK (doxorubicin)</li> <li>• Hospira UK (5-fluorouracil, octreotide)</li> <li>• Janssen (doxorubicin)</li> <li>• medac GmbH (5-fluorouracil, dacarbazine, doxorubicin, lomustine)</li> <li>• Merck Sharp and Dohme (interferon alfa-2b)</li> <li>• Novartis (octreotide long acting release)</li> <li>• Pfizer (doxorubicin)</li> <li>• Roche Products (interferon alfa)</li> <li>• Sun Pharmaceuticals UK (octreotide)</li> <li>• Teva Pharma (doxorubicin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Colorectal Cancer Group</li> <li>• Cochrane Metabolic and Endocrine</li> </ul>

National Institute for Health and Care Excellence

Matrix for the technology appraisal of everolimus, lanreotide, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression [ID858]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Institute of Radiology</li> <li>• British Nuclear Medicine</li> <li>• British Society of Gastroenterology</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> <li>• CRUK, ECMC and UK Radiopharmacy Group Taskforce (CERT)</li> <li>• Internal Dosimetry Users Group (IDUG)</li> <li>• Institute of Physics and Engineering Medicine</li> <li>• National Pharmacy Association</li> <li>• Pancreatic Cancer Action</li> <li>• Pancreatic Society of Great Britain and Ireland</li> <li>• PLANETS</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• Society for Endocrinology</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Endocrine Pathology Society (UKEPS)</li> <li>• UK Health Forum</li> <li>• UK and Ireland NET Society (UKINETS)</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Newcastle Gateshead CCG</li> <li>• NHS Sutton CCG</li> <li>• Welsh Government</li> </ul>	<p>Disorders Group</p> <ul style="list-style-type: none"> <li>• Cochrane Upper Gastrointestinal and Pancreatic Diseases Group</li> <li>• Core – The Digestive Disorders Foundation</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Pancreatic Cancer Research Fund</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### **DEFINITIONS OF CONSULTEES AND COMMENTATORS**

National Institute for Health and Care Excellence

Matrix for the technology appraisal of everolimus, lanreotide, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression [ID858]

### **MTA Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.